

1 **Bridging the Sequencing Gap: N501Y SNP RT-qPCR Assay Detects First SARS-CoV-2 Beta**  
2 **Variant in the Philippines**

3 Samantha Louise P. Bado<sup>1</sup>, Niquitta B. Galap<sup>1</sup>, Joanna Ina G. Manalo<sup>1</sup>, Othoniel Jan T. Onza<sup>1</sup>, Mary  
4 Rose B. Pelingon<sup>1</sup>, Joy Mariette L. Parayray<sup>1</sup>, Justine Mae Palciso<sup>1</sup>, Karen Iana C. Tomas<sup>1</sup>, Miguel  
5 Francisco B. Abulencia<sup>1</sup>, Francisco Gerardo M. Polotan<sup>1</sup>, Lei Lanna M. Dancel<sup>1</sup>, Amalea Dulcene  
6 Nicolasora<sup>1\*</sup>

7 <sup>1</sup>Advanced Molecular Technologies Laboratory, Research Institute for Tropical Medicine, Philippines

8 \*corresponding author

9 Email: amaleanicolasora@gmail.com

10 **ABSTRACT**

11 Whole genome sequencing (WGS) is used extensively in identifying SARS-CoV-2 variants. However,  
12 this method requires stringent sample acceptance criteria, long turn-around time (TAT), expensive  
13 processing and maintenance costs, and highly skilled staff. Although sequencing offers comprehensive  
14 pathogen insights, a cost-effective tool with faster TAT is beneficial in detecting SARS-CoV-2 variants  
15 of concern (VOCs). Here, we used a single nucleotide polymorphism (SNP) RT-qPCR assay to detect  
16 the N501Y mutation in banked SARS-CoV-2 RNA extracts (N=452) collected from December 2020 to  
17 April 2021. Of the SARS-CoV-2 positives (n=367), 22% carried the N501Y mutation and were  
18 classified as probable VOCs. This includes a sample that was confirmed to belong to the Beta lineage  
19 and was collected earlier than the first reported Beta variant in the country suggesting an earlier  
20 emergence of the variant. Validation experiments for the SNP RT-qPCR assay showed a limit of  
21 detection (LOD) of 3.01 copies/ $\mu$ L for both N501 and 501Y targets. A 99.35% concordance with partial  
22 S gene Sanger sequencing was observed confirming the presence of the N501Y SNP in 83 samples. In  
23 conclusion, the optimized SNP RT-qPCR assay serves as an important complementary or alternative  
24 tool for detecting probable SARS-CoV-2 variants, ensuring that samples ineligible for WGS are not  
25 overlooked. This effectively resolves sequencing gaps, including stringent sample acceptance criteria,  
26 extended TAT, and rigorous data analysis. Therefore, embracing this technology provides a rapid,  
27 economical, and dependable solution for managing pathogens of public health concern.

28 Keywords: SARS-CoV-2, SNP RT-qPCR, N501Y mutation, Philippines

29 **INTRODUCTION**

30 The global emergence of SARS-CoV-2 variants of concern (VOCs) heightened the need for genomic  
31 surveillance systems to maintain effective public health interventions during the COVID-19  
32 pandemic(1). In late 2020, an emergence of mutations enhancing viral pathogenicity, transmissibility,  
33 and antigenicity were observed(2). Three independent SARS-CoV-2 lineages, B.1.1.7/Alpha(3),  
34 B.1.351/Beta(4), and P.1/Gamma(5), were introduced and rapidly multiplied in the population. While

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

35 these variants are characterized by a myriad of mutations across their genomes, they share the key spike  
36 gene mutation N501Y(6). The mutation was identified as a possible determinant of enhanced infection,  
37 providing the virus with a more efficient viral entry and the ability to evade anti-spike protein  
38 antibodies(6–10).

39 The World Health Organization (WHO) recommended whole genome sequencing (WGS) for detecting  
40 and identifying emerging SARS-CoV-2 variants(11). However, using such technology proves to be  
41 challenging in resource-limited countries such as the Philippines due to its expensive processing and  
42 maintenance costs. Additionally, the long turnaround time, stringent sample acceptability criteria, and  
43 high technical requirements make it disadvantageous, especially in outbreak scenarios. Thus, alternative  
44 methods with rapid and efficient workflows are needed to allow SARS-CoV-2 variant screening(12).

45 An RT-qPCR assay that targets variant-specific SNP mutations like N501Y can be used as a screening  
46 tool for early variant classification(11). Laboratory-developed SNP RT-qPCR assays were implemented  
47 in the surveillance measures in several countries, which allowed them to screen and identify probable  
48 variants rapidly(13–17). In this paper, we optimized and used a SNP RT-qPCR assay to screen for the  
49 variant-associated N501Y amino acid substitution in banked SARS-CoV-2 samples. We also describe  
50 how it helped identify a missed Beta variant case in the Philippines.

## 51 **MATERIALS AND METHODS**

### 52 **Ethical statement**

53 All samples, protocols, and procedures described in this study are approved by the Research Institute  
54 for Tropical Medicine Institutional Review Board (RITM-IRB) with IRB Number 2022-43. The written  
55 informed consent requirement was waived based on the context of the emerging outbreak response.

### 56 **Clinical specimens**

57 RNA extracts from December 2020 to April 2021 collected from the National Capital Region (NCR)  
58 and Region IV-A in the Philippines were acquired from the RITM Advanced Molecular Technologies  
59 Laboratory (RITM-AMTL) COVID-19 specimen bank. Four hundred fifty-two (452) archived RNA  
60 extracts of PCR-confirmed SARS-CoV-2 negative ( $n = 85$ ) and positive ( $n = 367$ ) samples were  
61 retrieved and tested at the RITM-AMTL. All patient samples were de-identified and anonymized in all  
62 materials and documents used in this study.

63 **cDNA synthesis**

64 Complementary DNA (cDNA) was synthesized from RNA extracts using Moloney Murine Leukemia  
65 Virus (M-MLV) Reverse Transcriptase with RNaseOUT™ Recombinant Ribonuclease Inhibitor and  
66 Random Primers according to the manufacturer’s protocol (Invitrogen, CA, USA).

67 **N501Y SNP RT-qPCR assay**

68 The synthesized cDNA was subsequently tested using the N501Y SNP RT-qPCR assay that targets the  
69 N501Y wild type and mutant alleles. All primers and probes (Table 1) were adapted from the National  
70 Institute of Infectious Diseases (NIID) of Japan(18). The SNP RT-qPCR mastermix has a total volume  
71 of 10µL containing 5µL 2X Taqman Fast Advanced Master Mix (Applied Biosystems, CA, USA),  
72 3.2µL UltraPure™ Distilled Water (Invitrogen, CA, USA), 0.6µM primers, 0.1µM probes, and 1µL  
73 cDNA template. The amplification of the N501 and 501Y targets was detected through the FAM and  
74 VIC channels, respectively. The thermocycling profile optimized was 60°C for 1 minute, 50°C for 2  
75 minutes, 95°C for 2 minutes, and 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds, then a cycle  
76 of 60°C for 1 minute, using the 7500 Fast Real-Time PCR System (Applied Biosystems, CA, USA).  
77 Laboratory-confirmed SARS-CoV-2 negatives served as the negative control, and *in vitro* transcribed  
78 N501 and 501Y oligonucleotides served as positive controls for each RT-qPCR run.

79 Table 1. List of primers, probes, and positive control sequences used for N501Y mutation detection.

Use	Name	Sequence (5' to 3')
	Forward Primer	CTTGTAATGGTGTTRAAGGTTTTAATTGT
	Reverse Primer	GGTGCATGTAGAAGTTCAAAAGAAAG
	N501 (wild type) Probe	FAM-CCAACACCATTAGTGGGTTG-MGB
	501Y (mutant) Probe	VIC-CCAACACCATAAGTGGGTTG-MGB
N501Y SNP RT-qPCR	N501 Control	CTTGTAATGGTGTGAAGGTTTTAATTGTTACTTTCCTTTACA ATCATATGGTTTCCAACCCACTAATGGTGTGGTTACCAACC ATACAGAGTAGTAGTACTTTCTTTTGAAGTTCTACATGCACC
	501Y control	CTTGTAATGGTGTGAAGGTTTTAATTGTTACTTTCCTTTACA ATCATATGGTTTCCAACCCACTTATGGTGTGGTTACCAACC ATACAGAGTAGTAGTACTTTCTTTTGAAGTTCTACATGCACC
Partial Spike gene Sanger sequencing	F46 Forward Primer	CCTTCACTGTAGAAAAAGGAATC
	R46 Reverse Primer	TGGAAACCATATGATTGTAAAGGA
	F47 Forward Primer	TATCAGGCCGGTAGCACAC
	R47 Reverse Primer	CATATGAGTTGTTGACATGTTTCAG

## 80 **N501Y SNP Assay Validation**

81 The SNP assay's limit of detection (LOD) was validated for both N501 and 501Y targets using *in vitro*  
82 transcribed N501 and 501Y oligonucleotides. Starting with  $3.01 \times 10^9$  copies/ $\mu$ L, 10-fold serial dilutions  
83 were performed down to  $3.01 \times 10^{-2}$  copies/ $\mu$ L. All dilutions were tested in triplicates. The last two  
84 dilutions with a 100% detection rate for each target were tested in 20 replicates. The lowest dilution  
85 with at least a 95% detection rate is considered the LOD.

86 A panel of four hundred fifty-two (452) samples that were previously tested for the presence of SARS-  
87 CoV-2 using a commercial kit (Sansure Biotech) were used in this study. The SARS-CoV-2-positives  
88 were classified according to the Ct values of their ORF1ab gene target during the initial screening test:  
89 Low Ct is less than 25, Mid Ct is between 25 and 30, and High Ct is greater than 30. The samples were  
90 tested using the N501Y SNP RT-PCR assay to confirm the assay's viability in detecting SARS-CoV-2  
91 and distinguishing between N501Y wild type and mutant relative to Ct values.

## 92 **PCR amplification and Partial Spike Gene Sanger Sequencing**

93 To evaluate the accuracy of the SNP RT-qPCR assay in detecting the N501Y SNP, a subset of 308  
94 SARS-CoV-2-positive samples were sequenced using the Sanger sequencing method. This method is  
95 the gold standard for identifying SNPs and basecalling accuracy. Primers adapted from the National  
96 Reference Center for Emerging Viral Infections(19) flanking the Spike gene region were used to  
97 amplify two overlapping fragments covering positions 914-1981 of the Spike gene.

98 The conventional PCR reactions were carried out using the Ex Taq® PCR kit (TaKaRa, Kusatsu,  
99 Japan). The first round PCR mastermix has a total volume of 20 $\mu$ L containing the F46 and R47 primers  
100 at 500nM each, 2.0 $\mu$ L of 10x Ex Taq buffer, 1.6 $\mu$ L of 10 $\mu$ M dNTP mix, 0.1 $\mu$ L of Taq enzyme, and  
101 0.1 $\mu$ L cDNA. Pre-denaturation was set at 94°C for 2 minutes, followed by 35 cycles of denaturation at  
102 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 1 minute, then  
103 followed by a final extension at 72°C for 10 minutes. Two separate hemi-nested PCR runs were  
104 performed, one using F46 and R46 primers and the other using F47 and R47 primers (see Table 1).  
105 Each reaction mix consists of 500nM each of the primers, 2.0 $\mu$ L of 10x Ex Taq buffer, 1.6 $\mu$ L of 10 $\mu$ M  
106 dNTP mix, 0.1 $\mu$ L of Taq enzyme, and 0.5  $\mu$ L of template with a total volume of 20 $\mu$ L. The PCR profile  
107 from the first round was altered for the nested round by reducing the extension stage from 1 minute to  
108 30 seconds at 72°C. The PCR products were visualized using agarose gel electrophoresis. Samples with  
109 clear, distinct bands were purified using PureLink PCR purification kit (Invitrogen, CA, USA)  
110 following the manufacturer's protocol. Samples were sent to a third-party sequencing facility for  
111 sequencing using the ABI 3730XL system.

## 112 **Sequence analysis**

113 Partial S gene sequences were trimmed and assembled using MEGA X and Aliview software(20,21),  
114 and alignment was done using the S gene reference sequence (EPI\_ISL\_402124). Consensus FASTA  
115 sequences were uploaded to the Stanford Coronavirus Antiviral & Resistance Database (CoVDB) to  
116 check for the presence of the N501Y mutation. The program uses the reference sequence Wuhan-Hu-1  
117 (NC\_045512.2) for alignment(22).


## 118 **Phylogenetic Analysis**

119 The N501Y-containing sample with the earliest collection date, PH-RITM-0142, was sequenced  
120 through a modified ARTIC protocol(23). Fifty-seven (57) of its closely related sequences from the  
121 Philippines (EPI\_SET\_230914kr) were obtained using *AudacityInstant* (V5.1.0) on GISAID(24) on  
122 September 12, 2023. The sequences were aligned using MAFFT v7.520(25) and a phylogenetic tree  
123 was generated using IQ-TREE v2.2.3(26) with a GTR nucleotide substitution model and a fixed clock  
124 rate. The resulting tree was input into TreeTime v0.10.1(27) with 1000 iterations for bootstrapping to  
125 generate a time-scaled phylogeny.

## 126 **RESULTS**

### 127 **N501Y SNP RT-qPCR Assay Validation**

128 The SNP RT-qPCR assay's limit of detection (LOD) was validated to be 3.01 copies/ $\mu$ L for both N501  
129 and 501Y targets with 100% and 95% detection rates in 20 replicates, respectively (see Table S1). All  
130 SARS-CoV-2 negative samples (n=85) also showed negative results using the SNP assay. Among the  
131 SARS-CoV-2-positives, 48 (13%) showed negative results and were not classified by the SNP RT-  
132 qPCR assay as either wild type or mutant as shown in Figure 1. Of these 48 samples, one had a mid-  
133 range Ct value and 47 exhibited a high Ct value for the SARS-CoV-2 PCR screening test. Figure 1  
134 illustrates a decreasing trend in the detection rate of the SNP RT-qPCR assay as the Ct value of the  
135 samples increases. The concordance rate between the commercial kit (Sansure Biotech) and the SNP  
136 RT-qPCR assay is 100% and 87% in SARS-CoV-2 negative and positive samples.



137

138 Figure 1. SARS-CoV-2 detection rate of N501Y SNP RT-qPCR assay based on Ct value  
 139 generated from the ORF1ab gene target of the Sansure RT-qPCR run. The samples were  
 140 classified based on the following scheme: Low Ct <25, Mid Ct 25-30, and High Ct >30.

141 Concordance testing with partial S gene Sanger sequencing using 308 SARS-CoV-2-positive samples  
 142 (225 wild types and 83 with N501Y mutation) shows an overall percent agreement (OPA) of 99.35%  
 143 where the SNP RT-qPCR assay correctly classified 306 samples. Only two samples containing the 501Y  
 144 mutation according to Sanger sequencing exhibited discordant results (see Table 2).

145 Table 2. Concordance testing results between N501Y SNP RT-qPCR assay and partial S gene Sanger  
 146 sequencing.

SNP detection	Sanger mutant (501Y)	Sanger wild type (N501)	Total
SNP detected (501Y)	81	0	81
SNP not detected (N501)	2	225	227
Total	83	225	308


147

### 148 Comparing the SARS-CoV-2 lineage frequency distribution using SNP RT-qPCR vs Whole 149 Genome Sequencing

150 Of the 452 samples subjected to N501Y SNP RT-qPCR, a shift in the proportion of samples without  
 151 the N501Y mutation (N501) to those with the N501Y mutation (501Y) was observed between

152 December 2020 and April 2021 (Figure 2A). The detection rate of N501Y mutants increased by 95.32%  
153 from December 2020 to April 2021. The increasing trend coincides with that of Philippine whole  
154 genome sequences as shown in Figure 2B. However, it can be noted that the detection of the spike  
155 mutation is earlier for the SNP RT-qPCR (December 2020) as compared to WGS (January 2021).  
156 Notably, one of the samples that carried the N501Y mutation, PH-RITM-0142, was later confirmed by  
157 WGS to be a Beta variant. The sample was collected on December 9, 2020, which is earlier than the  
158 first reported Beta case in the country.


159 The prevalence of the N501Y mutation among tested samples aligns with the increase in confirmed  
160 cases of SARS-CoV-2 and the shift from the predominantly circulating lineage B.1.1.63 to the Alpha  
161 and Beta variants (Figure 3). However, sequencing data suggests that the first Beta variant cases were  
162 only introduced in the country around February 2021, which contrasts with our identification of a Beta  
163 variant sampled in December 2020.



164

165 Figure 2. (A) Detection rate of N501 and 501Y among SARS-CoV-2 positive samples from  
166 December 2020 to April 2021 using SNP RT-qPCR, (B) Philippine whole genome  
167 sequences collected between December 2020 and April 2021 carrying the spike mutation.






168

169 Figure 3. Number of sequenced genomes for each major variant (bars) and confirmed  
 170 COVID-19 cases (black solid line). D614G corresponds to non-major variants carrying the  
 171 D614G mutation.

172 **Phylogenetic Analysis**

173 Fifty-seven (57) B.1.351/Beta sequences collected in the Philippines that were closely related to PH-  
 174 RITM-0142 were generated using *AudacityInstant* (V5.1.0) on GISAID. In Figure 4, phylogenetic  
 175 analysis revealed that the PH-RITM-0142 B.1.351/Beta variant was introduced earlier than what was  
 176 reported to be the first case.



177

178 Figure 4. Phylogenetic analysis of the first N501Y case - PH-RITM-0142 - and its closest  
 179 sequences collected in the Philippines.



## 180 DISCUSSION

181 This study documents how we developed, optimized, and validated a SNP RT-qPCR assay to detect the  
182 N501Y mutation in archived SARS-CoV-2 samples collected from NCR and Region IV-A in the  
183 Philippines from December 2020 to April 2021. Our findings demonstrate its potential use in public  
184 health emergency response. N501Y is a key spike gene mutation shared by the Alpha, Beta, and Gamma  
185 variants(28), which were VOCs circulating globally at the time of collection of the archived samples.  
186 The first reported VOC case in the Philippines belonged to the Alpha lineage and was reported on  
187 January 13, 2021(29,30), although current data from GISAID shows that the Alpha variant was present  
188 as early as December 10, 2020 (EPI\_ISL\_1081795; <https://doi.org/10.55876/gis8.240515yr>). Data also  
189 shows that the first Beta case detected in the country was on January 31, 2021 (EPI\_ISL\_4743768;  
190 <https://doi.org/10.55876/gis8.240515ay>). Interestingly, in testing the archived samples, we detected the  
191 N501Y mutation from a sample collected on December 9, 2020, later confirmed by WGS to be of  
192 B.1.351/Beta lineage. The sample initially did not meet the stringent criteria for WGS since its ORF1ab  
193 Ct value is 32.63, which is beyond the recommended Ct value of  $\leq 30$ (31). This case highlights a gap in  
194 variant surveillance efforts, where samples with Ct values exceeding the eligibility criteria for WGS  
195 might be excluded from sequencing, potentially leading to the missed detection of important variants.  
196 In acknowledgment of such instances, non-sequencing methods like our optimized PCR-based SNP  
197 (N501Y) detection assay become a crucial source of information for rapid variant detection.

198 Our optimized SNP RT-qPCR assay demonstrates high concordance with partial S gene Sanger  
199 sequencing in detecting the N501Y SNP mutation. These findings signify the potential impact of  
200 utilizing rapid detection methods, in complementary with sequencing methodologies, in the quick  
201 estimation of the prevalence of probable variants in the community to help facilitate immediate  
202 preventive measures against its spread.

203 Analytical performance validation of our SNP RT-qPCR assay showed an LOD of 3.01 copies/ $\mu$ L for  
204 both targets in the validation experiments. When compared with a commercial SARS-CoV-2 diagnostic  
205 kit that targets the N and ORF1ab SARS-CoV-2 genes in a panel of clinical respiratory samples with  
206 low- intermediate- and high-concentration of SARS-CoV-2 genetic material, our in-house SNP  
207 (N501Y) assay could only detect SARS-CoV-2 from 46% of samples with Ct values  $>30$  (estimated to  
208 have low SARS-CoV-2 genetic material concentration) and subsequently classify them as either wild  
209 type or mutant for the N501Y mutation. While this indicates that our SNP assay has a lower analytical  
210 sensitivity than the comparator commercial SARS-CoV-2 diagnostic kit whose LOD is 0.2  
211 copies/ $\mu$ L(32), we emphasize that the assay is not meant to be used as a standalone diagnostic test for  
212 SARS-CoV-2. Its primary utility is for detecting the target SNP, in this case, the N501Y mutation.

213

214 In terms of detecting the N501Y SNP, the assay exhibited high diagnostic specificity and sensitivity  
215 with an overall percent agreement (OPA) of 99.35% relative to Sanger sequencing. These results show  
216 that the assay is sufficiently specific and sensitive in detecting the N501Y mutation. This makes it a  
217 useful tool for screening for probable variants, followed by sequencing as a confirmatory step.

218

219 Our retrospective testing revealed that B.1.351/Beta was detected in a sample (PH-RITM-0142)  
220 collected on December 9, 2020, from a high-risk patient with no known exposure and travel history.  
221 This finding suggests earlier circulation of the Beta variant compared to the officially reported date of  
222 March 2, 2021, which was based on the earliest confirmed case at that time, whose sample was collected  
223 in late January(33). This also shows that SARS-CoV-2 VOCs were already circulating in the country  
224 before its first public report in January 2021. Initially, the sample was not included in the subset that  
225 was routinely sequenced for surveillance since its RT-qPCR results showed a high Ct value (32.63)  
226 indicating weak positivity. However, since the SNP RT-qPCR results showed that it carried the N501Y  
227 mutation, we subjected it to WGS using Oxford Nanopore Technology (ONT) for confirmation. Results  
228 showed that the sample belonged to the B.1.351/Beta lineage with 81% genome coverage. Moreover,  
229 our phylogenetic analysis in Figure 4 further supports the claim that PH-RITM-0142 predates the Beta  
230 transmission window in the Philippines, which occurred from January to August 2021 with the first  
231 officially reported first case on January 31, 2021. Additionally, it is not linked to the subsequent increase  
232 in B.1.351/Beta cases. These results are crucial for determining when and how the B.1.351/Beta variant  
233 entered and spread in the Philippines. It suggests that there was an introduction of Beta earlier than  
234 initially thought.

235

236 While genomic sequencing is important for surveillance, it is still limited to specialized and highly  
237 equipped laboratories. It also requires high quality and concentration of SARS-CoV-2 viral RNA as a  
238 quality control checkpoint. In the context of outbreak response, a PCR-based method that can screen  
239 for probable variants and be deployed more easily might have a greater impact on disease control  
240 measures. A multi-step screening concept was developed across diagnostic and research laboratories in  
241 Switzerland to understand the spread of VOC and adapt public health interventions. This includes  
242 microbiological risk definition using S-dropout as an indicator for the Alpha lineage, and the  
243 establishment of N501Y-specific RT-PCR assays(15). Another research initiative opted to use an RT-  
244 qPCR screening test, facilitating the analysis of a larger sample size within a shorter timeframe and at  
245 a reduced cost(16). They identified variants in samples positive for SARS-CoV-2 by an RT-qPCR  
246 mutation screening kit and subsequently confirmed through Next Generation Sequencing (NGS).  
247 During the early stages of the COVID-19 pandemic in Argentina, variant surveillance was initiated  
248 using WGS. In February 2021, they changed their strategy to partial S gene sequencing due to a  
249 significant increase in demand for WGS. However, both sequencing approaches were time-consuming

250 which resulted in delayed identification of variants. They then established an algorithm using an RT-  
251 qPCR strategy that targeted the N501Y, E484K, and L452 mutations(17). Similarly, our optimized  
252 assay would have been a useful tool for more rapid identification of variants in the country had it been  
253 included in our surveillance initiatives as a screening step. Our findings provide use-case evidence of  
254 how the limitations of WGS have a big impact on generating an accurate picture of lineage distribution  
255 and replacement events. Additionally, it provides evidence of the utility of SNP RT-qPCR assays for  
256 variant detection and surveillance in tandem with WGS.

257

258 Despite its remarkable diagnostic performance, our optimized assay does not differentiate between the  
259 VOCs that share the N501Y SNP which warrants a confirmatory sequencing step to determine the  
260 sample's lineage. Moreover, the assay only targets the N501Y SNP which makes it inapplicable for  
261 emerging SARS-CoV-2 VOCs that do not carry the SNP. Additional targets may be included similar to  
262 other assays that have already been developed(34–36) to screen for other circulating variants. There is  
263 a need to continually update the SNP RT-qPCR assays to accommodate EREIDs that rapidly evolve.  
264 We only tested archived samples from NCR and Region IV with the earliest collection date of December  
265 2020. While the assay was able to uncover a shift in the N501Y SNP's detection rate, we may not have  
266 captured potential earlier cases predating December 2020 from other regions. This limits our  
267 comprehension of the introductory events of VOCs in the country.

268 Using rapid tools for detecting VOCs is critical, especially during their early stage of spread. As  
269 demonstrated by the detection of an unreported earlier VOC case, PCR-based assays offer the fastest  
270 and most practical approach for controlling the spread of new variants which warrants prioritization of  
271 detection over depth of information. Although currently limited to N501Y mutations, the optimized  
272 SNP RT-qPCR assay can be customized to detect other critical mutations, preparing us to identify  
273 emerging viral strains with higher public health significance. Integrating these assays into testing  
274 algorithms for outbreak response offers a valuable tool for the immediate implementation of efficient  
275 evidenced-based control measures. This proactive approach strengthens our preparedness and response  
276 to emerging infectious diseases.

## 277 **CONCLUSIONS**

278 In testing archived samples using the optimized highly sensitive and specific SNP RT-qPCR assay, we  
279 detected an earlier Beta variant case in the country that was previously missed because the sample failed  
280 to meet the stringent WGS eligibility criteria. As an alternative to the labor- and resource-intensive  
281 WGS method, or as a complementary method for variant detection, the assay offers a cheap and rapid  
282 way to screen for probable variants and estimate their prevalence in the community. We demonstrate  
283 here that PCR-based SNP variant detection assays can be an effective complementary tool in assembling

284 a more accurate picture of SARS-CoV-2 transmission. This highlights its utility for rapid outbreak  
285 response and the conduct of subsequent surveillance for emerging SARS-CoV-2 variants. Moreover,  
286 its adaptability is valuable in addressing potential outbreaks caused by novel pathogens. Our study also  
287 highlights the importance of developing and maintaining in-house capacity for the development of  
288 molecular assays that can promptly be adjusted to suit the evolving testing needs given the volatile  
289 nature of emerging and re-emerging infectious diseases. As we navigate the evolving challenges of  
290 infectious diseases, the importance of the adaptability and effectiveness of these assays becomes  
291 apparent, ensuring we remain at the lead in the continuous fight against emerging pathogens.

## 292 **ACKNOWLEDGMENT**

293 We sincerely thank all the data contributors, namely the authors and their originating laboratories  
294 responsible for obtaining the specimens, as well as the submitting laboratories for generating the genetic  
295 sequences and metadata. This research is based on their valuable contributions through the GISAID  
296 Initiative. We would also like to acknowledge Aldrin V. Imbag and Fatima Rose S. Guemo for  
297 maintaining the HPC cluster used in this study. The preparation of this manuscript benefited from  
298 guidance and discussion at Project BUKLOD's Academic Writing Course in June 2023 (funded by the  
299 German Alliance for Global Health Research).

300 **SUPPLEMENTAL DATA**

301 Table S1. Limit of detection raw data.

Replicate	N501		501Y	
	3.01 copies/ $\mu$ L	0.301 copies/ $\mu$ L	3.01 copies/ $\mu$ L	0.301 copies/ $\mu$ L
1	Detected	Not Detected	Detected	Detected
2	Detected	Not Detected	Detected	Not Detected
3	Detected	Not Detected	Detected	Detected
4	Detected	Not Detected	Detected	Not Detected
5	Detected	Not Detected	Detected	Detected
6	Detected	Detected	Detected	Detected
7	Detected	Not Detected	Detected	Detected
8	Detected	Not Detected	Detected	Detected
9	Detected	Not Detected	Detected	Detected
10	Detected	Not Detected	Detected	Detected
11	Detected	Not Detected	Detected	Not Detected
12	Detected	Detected	Detected	Not Detected
13	Detected	Not Detected	Detected	Detected
14	Detected	Not Detected	Detected	Not Detected
15	Detected	Not Detected	Not Detected	Not Detected
16	Detected	Detected	Detected	Not Detected
17	Detected	Detected	Detected	Not Detected
18	Detected	Not Detected	Detected	Not Detected
19	Detected	Not Detected	Detected	Detected
20	Detected	Not Detected	Detected	Detected
No. of Replicates	20	20	20	20
No. of positives	20	4	19	11
<b>% Detected</b>	<b>100</b>	<b>20</b>	<b>95</b>	<b>55</b>

303 **Data Availability**

304 GISAID Identifier: EPI\_SET\_230914kr

305 <https://doi.org/10.55876/gis8.230914kr>

306

307 All genome sequences and associated metadata in this dataset are published in GISAID's EpiCoV  
308 database. To view the contributors of each individual sequence with details such as accession number,  
309 Virus name, Collection date, Originating Lab and Submitting Lab, and the list of Authors, visit  
310 [10.55876/gis8.230914kr](https://doi.org/10.55876/gis8.230914kr)

311

312 **Data Snapshot**

313

- 314 ● EPI\_SET\_230914kr is composed of 57 individual genome sequences.
- 315 ● The collection dates range from 2021-02-08 to 2021-06-28;
- 316 ● Data were collected in 1 countries and territories;
- 317 ● All sequences in this dataset are compared relative to hCoV-19/Wuhan/WIV04/2019 (WIV04),  
318 the official reference sequence employed by GISAID (EPI\_ISL\_402124). Learn more at  
319 <https://gisaid.org/WIV04>.

320 **REFERENCES**

- 321 1. WHO. Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022–  
322 2032. 2022; Available from: <https://www.who.int/publications-detail-redirect/9789240046979>
- 323 2. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2  
324 variants, spike mutations and immune escape. *Nat Rev Microbiol*. 2021 Jul;19(7):409–24.
- 325 3. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. Preliminary genomic  
326 characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations  
327 [Internet]. 2020 Dec. Available from: <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>  
328
- 329 4. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-  
330 CoV-2 variant of concern in South Africa. *Nature*. 2021 Apr 15;592(7854):438–43.
- 331 5. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology  
332 of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science*. 2021 May 21;372(6544):815–21.
- 333 6. Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant  
334 strains of SARS-CoV-2 in the United Kingdom, October to November 2020. *Eurosurveillance* [Internet].  
335 2021 Jan 7 [cited 2023 Sep 27];26(1). Available from:  
336 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.26.1.2002106>
- 337 7. Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, et al. N501Y mutation of spike protein in SARS-CoV-2  
338 strengthens its binding to receptor ACE2. *eLife*. 2021 Aug 20;10:e69091.
- 339 8. Williams AH, Zhan CG. Fast Prediction of Binding Affinities of the SARS-CoV-2 Spike Protein Mutant  
340 N501Y (UK Variant) with ACE2 and Miniprotein Drug Candidates. *J Phys Chem B*. 2021 May  
341 6;125(17):4330–6.
- 342 9. Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, et al. The N501Y spike substitution enhances SARS-  
343 CoV-2 transmission [Internet]. *Microbiology*; 2021 Mar [cited 2023 Nov 30]. Available from:  
344 <http://biorxiv.org/lookup/doi/10.1101/2021.03.08.434499>
- 345 10. Sandoval Torrientes M, Castelló Abietar C, Boga Riveiro J, Álvarez-Argüelles ME, Rojo-Alba S, Abreu  
346 Salinas F, et al. A novel single nucleotide polymorphism assay for the detection of N501Y SARS-CoV-2  
347 variants. *J Virol Methods*. 2021 Aug;294:114143.
- 348 11. ECDC, WHO. Methods for the detection and characterisation of SARS-CoV-2 variants - second update  
349 [Internet]. 2022 Aug. Available from: [https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-char-SARS-CoV-2-variants\\_2nd%20update\\_final.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-char-SARS-CoV-2-variants_2nd%20update_final.pdf)  
350
- 351 12. Specchiarello E, Matusali G, Carletti F, Gruber CEM, Fabeni L, Minosse C, et al. Detection of SARS-CoV-  
352 2 Variants via Different Diagnostics Assays Based on Single-Nucleotide Polymorphism Analysis.  
353 *Diagnostics*. 2023 Apr 27;13(9):1573.
- 354 13. Abdulnoor M, Eshaghi A, Perusini SJ, Broukhanski G, Corbeil A, Cronin K, et al. Real-Time RT-PCR  
355 Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2  
356 Associated with B.1.1.7 Variant of Concern. Bard JD, editor. *Microbiol Spectr*. 2022 Feb 23;10(1):e00681-  
357 21.
- 358 14. Gomes L, Jeewandara C, Jayadas TP, Dissanayake O, Harvie M, Guruge D, et al. Surveillance of SARS-  
359 CoV-2 variants of concern by identification of single nucleotide polymorphisms in the spike protein by a  
360 multiplex real-time PCR. *J Virol Methods*. 2022 Feb;300:114374.



- 361 15. Goncalves Cabecinhas AR, Roloff T, Stange M, Bertelli C, Huber M, Ramette A, et al. SARS-CoV-2  
362 N501Y Introductions and Transmissions in Switzerland from Beginning of October 2020 to February  
363 2021—Implementation of Swiss-Wide Diagnostic Screening and Whole Genome Sequencing.  
364 *Microorganisms*. 2021 Mar 25;9(4):677.
- 365 16. Muñoz-Valle JF, Venancio-Landeros AA, Sánchez-Sánchez R, Reyes-Díaz K, Galindo-Ornelas B,  
366 Hernández-Monjaraz WS, et al. An Upgrade on the Surveillance System of SARS-CoV-2: Deployment of  
367 New Methods for Genetic Inspection. *Int J Mol Sci*. 2022 Mar 15;23(6):3143.
- 368 17. Castro GM, Sicilia P, Bolzon ML, Lopez L, Barbás MG, Pisano MB, et al. Tracking SARS-CoV-2 Variants  
369 Using a Rapid Typification Strategy: A Key Tool for Early Detection and Spread Investigation of Omicron  
370 in Argentina. *Front Med*. 2022 May 17;9:851861.
- 371 18. Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, et al. Non-Omicron breakthrough infection  
372 with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5  
373 neutralization. *iScience*. 2023 Feb;26(2):105969.
- 374 19. Université de Genève, Hôpitaux Universitaires de Genève. Protocol for specific RT-PCRs for marker  
375 regions of the Spike region indicative of the UK SARS-CoV2 variant B.1.1.7 and the South African variant  
376 501Y.V2 [Internet]. 2020 Dec. Available from:  
377 [https://www.hug.ch/sites/interhug/files/structures/laboratoire\\_de\\_virologie/protocol\\_amplification\\_voc\\_20](https://www.hug.ch/sites/interhug/files/structures/laboratoire_de_virologie/protocol_amplification_voc_20201201_uk_geneva.pdf)  
378 [20201201\\_uk\\_geneva.pdf](https://www.hug.ch/sites/interhug/files/structures/laboratoire_de_virologie/protocol_amplification_voc_20201201_uk_geneva.pdf)
- 379 20. Larsson A. AliView: a fast and lightweight alignment viewer and editor for large datasets. *Bioinformatics*.  
380 2014 Nov 15;30(22):3276–8.
- 381 21. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis  
382 across Computing Platforms. Battistuzzi FU, editor. *Mol Biol Evol*. 2018 Jun 1;35(6):1547–9.
- 383 22. Stanford Coronavirus Antiviral & Resistance Database (CoVDB) [Internet]. [cited 2023 Oct 9]. Available  
384 from: <https://covdb.stanford.edu/sierra/sars2/by-sequences/>
- 385 23. Quick J. nCoV-2019 sequencing protocol v1 [Internet]. 2020 [cited 2024 Jun 18]. Available from:  
386 <https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w>
- 387 24. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality.  
388 *Eurosurveillance* [Internet]. 2017 Mar 30 [cited 2023 Oct 4];22(13). Available from:  
389 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.13.30494>
- 390 25. Katoh K. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform.  
391 *Nucleic Acids Res*. 2002 Jul 15;30(14):3059–66.
- 392 26. Nguyen LT, Schmidt HA, Von Haeseler A, Minh BQ. IQ-TREE: A Fast and Effective Stochastic  
393 Algorithm for Estimating Maximum-Likelihood Phylogenies. *Mol Biol Evol*. 2015 Jan;32(1):268–74.
- 394 27. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. *Virus Evol*  
395 [Internet]. 2018 Jan 1 [cited 2023 Nov 30];4(1). Available from:  
396 <http://academic.oup.com/ve/article/doi/10.1093/vex042/4794731>
- 397 28. Young M, Crook H, Scott J, Edison P. Covid-19: virology, variants, and vaccines. *BMJ Med*. 2022  
398 Mar;1(1):e000040.
- 399 29. DOH. PH Genomic Biosurveillance Detects SARS-CoV-2 UK Variant [Internet]. 2021 Jan. Available  
400 from: [https://doh.gov.ph/doh-press-release/PH-GENOMIC-BIOSURVEILLANCE-DETECTS-SARS-](https://doh.gov.ph/doh-press-release/PH-GENOMIC-BIOSURVEILLANCE-DETECTS-SARS-COV-2-UK-VARIANT)  
401 [COV-2-UK-VARIANT](https://doh.gov.ph/doh-press-release/PH-GENOMIC-BIOSURVEILLANCE-DETECTS-SARS-COV-2-UK-VARIANT)
- 402 30. PGC. PGC SARS-CoV-2 Bulletin No. 6: First case of the new variant under Lineage B.1.1.7 detected in  
403 the Philippines [Internet]. 2021 Jan. Available from: <https://pgc.up.edu.ph/pgc-sars-cov-2-bulletin-no-6/>

- 404 31. Pan American Health Organization. Guidance for SARS-CoV-2 samples selection for genomic  
405 characterization and surveillance [Internet]. 2021. Available from:  
406 <https://www.paho.org/en/file/82020/download?token=dUPSGHUm>
- 407 32. Sansure Biotech, Inc. Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence  
408 Probing) Instructions for Use V02. 2022.
- 409 33. Ropero G. PH reports 10,019 more COVID-19 cases, total now at 2,632,881. ABS-CBN News. 2021 Oct 7;
- 410 34. Martinez M, Nguyen PV, Su M, Cardozo F, Valenzuela A, Franco L, et al. SARS-CoV-2 Variants in  
411 Paraguay: Detection and Surveillance with an Economical and Scalable Molecular Protocol. *Viruses*. 2022  
412 Apr 22;14(5):873.
- 413 35. Nörz D, Grunwald M, Tang HT, Olearo F, Günther T, Robitaille A, et al. Rapid Automated Screening for  
414 SARS-CoV-2 B.1.617 Lineage Variants (Delta/Kappa) through a Versatile Toolset of qPCR-Based SNP  
415 Detection. *Diagnostics*. 2021 Oct 1;11(10):1818.
- 416 36. Wang H, Miller JA, Verghese M, Sibai M, Solis D, Mfuh KO, et al. Multiplex SARS-CoV-2 Genotyping  
417 Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance.  
418 McAdam AJ, editor. *J Clin Microbiol*. 2021 Jul 19;59(8):e00859-21.

419